- Home
- AVTX vs AGEN Comparison
AVTX vs AGEN Comparison
Compare AVTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- AGEN
- Stock Information
- Founded
- AVTX 2011
- AGEN 1994
- Country
- AVTX United States
- AGEN United States
- Employees
- AVTX N/A
- AGEN N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVTX Health Care
- AGEN Health Care
- Exchange
- AVTX Nasdaq
- AGEN Nasdaq
- Market Cap
- AVTX 138.8M
- AGEN 142.8M
- IPO Year
- AVTX 2015
- AGEN 2000
- Fundamental
- Price
- AVTX $13.50
- AGEN $4.28
- Analyst Decision
- AVTX Strong Buy
- AGEN Buy
- Analyst Count
- AVTX 9
- AGEN 2
- Target Price
- AVTX $30.14
- AGEN $14.50
- AVG Volume (30 Days)
- AVTX 451.4K
- AGEN 456.4K
- Earning Date
- AVTX 11-06-2025
- AGEN 11-11-2025
- Dividend Yield
- AVTX N/A
- AGEN N/A
- EPS Growth
- AVTX N/A
- AGEN N/A
- EPS
- AVTX N/A
- AGEN N/A
- Revenue
- AVTX $441,000.00
- AGEN $101,706,000.00
- Revenue This Year
- AVTX N/A
- AGEN $60.49
- Revenue Next Year
- AVTX N/A
- AGEN N/A
- P/E Ratio
- AVTX N/A
- AGEN N/A
- Revenue Growth
- AVTX N/A
- AGEN N/A
- 52 Week Low
- AVTX $3.39
- AGEN $1.38
- 52 Week High
- AVTX $16.00
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- AVTX 65.78
- AGEN 44.68
- Support Level
- AVTX $12.41
- AGEN $3.78
- Resistance Level
- AVTX $14.73
- AGEN $4.80
- Average True Range (ATR)
- AVTX 0.94
- AGEN 0.26
- MACD
- AVTX 0.13
- AGEN -0.01
- Stochastic Oscillator
- AVTX 70.97
- AGEN 40.34
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).